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Background: Transcription of the cathelicidin antimicrobial peptide (CAMP) gene is induced by binding of the
bioactive form of vitamin D, 1,25-dihydroxyvitamin D, to the vitamin D receptor. Significant levels of the protein
hCAP18/LL-37 are found in the blood and may protect against infection and/or sepsis. We hypothesized that
serum vitamin D levels may modulate the circulating levels of hCAP18. Only three studies have shown a positive
correlation between circulating 25-hydroxyvitamin D and hCAP18 levels. Here we provide additional evidence
for such a correlation in healthy, middle-aged adults.
Findings: Serum levels of 25-hydroxyvitamin D [25(OH)D] and plasma levels of hCAP18 were determined in
19 healthy middle-aged (mean of 50.1 years) adult men and women. Plasma hCAP18 concentrations correlated
with serum 25(OH)D concentrations in subjects with 25(OH)D levels ≤ 32 ng/ml (r = 0.81, p < 0.005) but not in
subjects with concentrations > 32 ng/ml (r = 0.19, p = 0.63).
Conclusions: We conclude that plasma hCAP18 levels correlate with serum 25(OH)D levels in subjects with
concentrations of 25(OH)D ≤ 32 ng/ml as opposed to those with concentrations > 32 ng/ml and that vitamin D
status may regulate systemic levels of hCAP18/LL-37.
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Background
CAMP gene expression is important in host defense as
mice and humans lacking hCAP18/LL-37 are susceptible
to bacterial infections in numerous tissues including
the skin, eye, urinary tract, colon and lung [1-11]. Also,
increasing hCAP18/LL-37 in these tissues helps reduce
and clear infection [12-14]. Collectively, these data
strongly implicate expression of the CAMP gene in
maintaining adequate host defense. In addition, the LL-37
peptide has additional biological activities that include
neutralizing LPS, chemoattraction of leukocytes and pro-
motion of wound healing and angiogenesis [15].
The human cathelicidin antimicrobial peptide (CAMP)
gene encodes an 18 kDa propeptide (hCAP18) that is
packaged in secondary granules of neutrophils and* Correspondence: adrian.gombart@oregonstate.edu
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reproduction in any medium, provided the orproteolytically cleaved to generate the mature antimi-
crobial peptide, LL-37, that kills invading pathogens
[16-19]. The CAMP gene is regulated at the level of tran-
scription by the bioactive form of vitamin D, 1,25(OH)2D,
and the vitamin D receptor [20-22]. The hCAP18/LL-37
protein is expressed by a wide array of immune cells
[23,24] and tissues that are constantly exposed to microbes
including the skin, mouth, airways, intestine and colon
and is secreted in saliva, sweat, semen and circulates at
high levels in the plasma [25-30]. In vitro administration
of 1,25(OH)2D induces CAMP gene expression in immune
and other epithelial barrier cells [20-22,31,32]. It has been
shown that adequate levels of serum 25(OH)D are required
for expression of hCAP18/LL-37 by immune-activated
macrophages [33], but the relationship between serum
25(OH)D and plasma hCAP18/LL-37 levels has been
unclear [34,35].
The biological importance of circulating hCAP18/
LL-37 is not well understood, but it may play a role in
protecting against infection and/or the development oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with the lowest levels of hCAP18 were at a greater than
2-fold risk of death of infectious causes, but a correlation
between 25(OH)D levels and hCAP18 was not observed
[34]. Also, in a study of patients with bone disease we
did not find a correlation [34,35]. On the other hand,
severely ill (sepsis and non-sepsis) patients were found to
have lower 25(OH)D and LL-37 than healthy subjects
and a positive correlation between vitamin D levels and
LL-37 was shown in all populations [36]. More recently,
Bhan and colleagues demonstrated that 25(OH)D levels
positively correlate with both baseline cathelicidin levels
and changes in cathelicidin levels after high-dose ergo-
calciferol treatment [37]. Interestingly, the positive cor-
relation only existed at 25(OH)D levels <32 ng/ml, but
not when the levels were >32 ng/ml [37]. The relation-
ship between vitamin D status and circulating hCAP18
levels has been inconsistent; therefore, we conducted a
prospective study in healthy middle-aged adults to test




A total of 19 healthy, volunteer adults were recruited
from the greater Salt Lake City metropolitan area (~40°
North latitude). The gender and racial composition, age,
vitamin D intake from a multivitamin and/or dietary
sources and average serum 25(OH)D levels are summar-
ized in Table 1. All subjects were known to be free
of disease and were not taking medication or a stand-
alone vitamin D product, but could have been taking a
multivitamin with vitamin D or other supplements that
do not contain vitamin D. All serum and plasma were
collected from each individual during the month of
December. Written informed consent for participation
in the study was obtained from participants. The proto-
col was approved by the ethics review committees at
USANA and OSU.
25(OH)D assay
To determine circulating 25-hydroxyvitamin D levels a
modified technique for vitamin D extraction and meas-
urement was developed [38,39]. Briefly, 100 μl of serum
was added to 400 μl of a 2:1 methanol:chloroform solu-
tion containing deuterated 25-hydroxyvitamin D3 as an
internal standard (40 ng/ml final concentration). To
achieve phase separation, 750 μl of ddH2O was added,Table 1 Characteristics of subjects enrolled (n = 19)
Subjects Male/Female Mean age Ethnicity**
19 10/9 50.1 16C/2A/1P
*C – Caucasian; A – Asian; P – Pacific Islander.
± Standard deviations indicated.mixed by vortexer, and centrifuged at 15,000 g for 2
min. The aqueous phase and debris between the two
phases were removed, discarded, and the remaining
solution dried to completion. The pellet was dissolved in
100 μl methanol and analyzed by injecting 10 μl into
an Agilent HPLC (Series 6410, Model G6410A, Santa
Clara, CA, USA). 25(OH)D3, 25(OH)D2 and the internal
standard were detected on an Agilent tandem mass
spectrometer (Series 6410, Model G6410A, Santa Clara,
CA, USA) using atmospheric pressure chemical ioni-
zation (APCI) detection. Concentrations of 25(OH)D3,
25(OH)D2 and the internal standard were determined
relative to authentic standards and corrected for recov-
ery. Average recovery was 92.2%. Intra-day coefficient of
variation was 4.7% and inter-day coefficient of variation
was 9.4%. The detection limit was determined to be less
than 1 ng/ml of all analytes. The results were directly
compared with two external, FDA-approved, clinical
laboratories (Quest Diagnostics and ZRT Laboratory,
Beaverton, OR) and levels determined by our assay
matched their results (data not shown).
Determination of circulating protein levels
The levels of hCAP18 (ng/ml) in each plasma sample
were determined using a non-commercial ELISA with
a detection limit of 0.084 ng/ml and an intra- and inter-
assay coefficient of variation of ≤6.3% [30].
Statistical analysis
Data was checked for normality with a Kolmogorov-
Smirnov test prior to all statistical analyses. Relation-
ships between variables were examined with a Pearson
Product Moment Linear correlation. All statistical ana-
lyses were performed with SysStat software (SigmaPlot
10.0, SigmaStat 3.5, Chicago, IL). Statistical Significance
was set at p < 0.05 (for correlation coefficients, n = 10,
r ≥ 0.632; n = 9, r ≥ 0.666).
Results
When analyzed as one group (n = 19; mean age 50.1 ±
8.4), no statistically significant correlation between
serum levels of 25(OH)D and plasma hCAP18 was iden-
tified (data not shown). Bhan and colleagues reported
a positive correlation only existed at 25(OH)D levels
<32 ng/ml, but not with higher levels [37]. Therefore,
subjects were separated into two groups based on serum
25(OH)D levels: those with levels ≤ 32 ng/ml and those
above. Interestingly, plasma hCAP18 concentrationsMean Vitamin D intake (IU) Mean serum 25(OH)D (ng/ml)
602.6 ± 362.3 33.4 ± 13.9
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tions in subjects with 25(OH)D levels ≤ 32 ng/ml (r =
0.81, p < 0.005) as compared to subjects with concentra-
tions > 32 ng/ml (r = 0.19, p = 0.63) (Figure 1 A & B).
When the cut-off was set at serum levels of 25(OH)D
less than 40 ng/ml, the correlation between 25(OH)D
and hCAP18 in subjects was non-significant ( r = 0.43,
p = 0.14). It was not possible to test cut-offs at serum
levels of 25(OH)D less than 25 or 20 ng/ml as the
number of subjects were too low for statistical power.
Discussion
With the discovery that bio-active forms of vitamin D
induce the expression of the CAMP gene, it has been
hypothesized that vitamin D status may affect the levels
of circulating hCAP18 [20,34]. In a study of dialysis
patients, those with the lowest circulating levels of
hCAP18 were at a greater than two-fold increased
risk of death of infectious causes, but a correlation
between serum 25(OH)D and hCAP18 levels was not
observed [34].
More recently, Bhan and colleagues discovered a posi-
tive correlation in healthy individuals (mean age 39) at
25(OH)D levels <32 ng/ml, but not when levels were
higher [37]. In their study, the 25(OH)D and cathelicidin
concentrations were rank transformed, leaving a possible
question as to the biological validity and interpretability
of the association. On the other hand, Jeng and collea-
gues observed a positive association between vitamin D
status and plasma LL-37 in sepsis, critically ill and healthy
patients without transforming the data [36]. Interestingly,
100% of the sepsis patients (mean age 54.0 ±17.1), 92% of
the critically ill patients (mean age 56.1 ±15.9) and 66.5%
of the healthy individuals (mean age 46.5 ±6.1) had
serum 25(OH)D levels below 30 ng/ml [36]. The
authors did not apply a cut-off for analysis, but the ma-
jority of their subjects were already below 32 ng/ml,
and it is possible that analysis of subjects >32 ng/ml 25A
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Figure 1 Correlation between serum 25(OH)D and plasma hCAP18 lev
25(OH)D concentrations (ng/ml) in subjects with 25(OH)D≤ 32 ng/ml (pan
concentrations > 32 ng/ml (panel B, n = 9, dotted regression line).(OH)D would have lacked the statistical power to dis-
cern such a trend. Similarly, in a study by Alvarez-
Rodriguez and colleagues of 71 healthy individuals with
about two-thirds of participants below 32 ng/ml serum
25(OH)D, a positive correlation between serum 25(OH)
D and LL-37 levels was observed [40]. On the other
hand, no relationship between maternal 25(OH)
D serum levels and LL-37 were detected in cord-blood
samples [41] or in patients with active pulmonary tuber-
culosis [42], but again these studies did not apply a cut-
off in the analysis. Interestingly, Alvarez-Rodriguez and
colleagues showed that LL-37 levels decreased with age
[40]; however, it also has been reported that LL-37 levels
increase with age [43,44]. A correlation with age could
not be examined in this study due to the limited num-
bers of subjects.
This study confirms the findings of the three earlier
studies described above [36,37,40] and further confirms
those of Bhan and colleagues [37] that plasma hCAP18
levels correlated with serum 25(OH)D in subjects with
25(OH)D concentrations ≤ 32 ng/ml as opposed to those
with concentrations > 32 ng/ml. These studies suggest
that there is a threshold for the biological effects of vita-
min D, as measured by 25(OH)D, at or around 32 ng/ml
particularly with regard to hCAP18/LL-37 blood levels.
To determine the exact threshold (and optimal circulat-
ing level of 25(OH)D) for each downstream effect of
vitamin D, further research needs to be conducted. Stud-
ies with much larger subject numbers and with a broad
range of serum 25(OH)D levels would allow testing
of different thresholds to determine if the cutoff is
higher or lower than 30–32 ng/ml. This study did not
show a correlation at a cutoff of 40 ng/ml 25(OH)D, but
we could not test lower cutoffs due to insufficient sub-
ject numbers.
Given the nature of the relationship between serum
25(OH)D and hCAP18/LL-37 levels, it is possible that
vitamin D supplementation or exposure to sunlight toB
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els. Plasma hCAP18 concentrations (ng/ml) correlated with serum
el A, n = 10, solid regression line) but not in subjects with
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systemic levels of hCAP18/LL-37, thus enhancing
protection against infection and/or sepsis. In support of
this, in vivo supplementation of individuals with serum
25(OH)D levels <32 ng/ml resulted in an increase in
hCAP18 levels in those individuals showing the greatest
increase in serum 25(OH)D [37]. In another study, sup-
plementation of normal and atopic dermatitis (AD)
patients with 4,000 IU oral vitamin D3 (cholecalciferol)
for 21 days resulted in a statistically significant increase
in cathelicidin expression in the AD lesions [45]. It was
not determined if supplementation improved immuno-
logic outcomes in these studies; therefore, future ran-
domized controlled trials are needed to establish an
immune enhancing role for vitamin D supplementation
and to determine optimal circulating levels.
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